131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat
This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG) and compare their effects on tumor response and associated side effects, to determine if one therapy is better than the other for people diagnosed with relapsed or persistent neuroblastoma.
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
|Eligible Ages||2 Years - 30 Years|
- - Patients must be > 24 months and < 30 years of age when registered on study.
- - Patients must have relapsed neuroblastoma, refractory neuroblastoma that had less than a partial response to standard treatment or persistent neuroblastoma that had at least a partial response to frontline therapy frontline therapy with > 3 residual lesions on end-induction MIBG scan.
- - Patients must have evidence of MIBG uptake into tumor at ≥ one site within 4 weeks prior to entry on study and subsequent to any intervening therapy.
- - Patients must have adequate heart, kidney, liver and bone marrow function.
- - Patients must have a dose of unpurged peripheral blood stem cells is 2.0 x 106 viable CD34+ cells/kg available.
- - They have had previous I-131 MIBG therapy - They have other medical problems that could get much worse with this treatment.
- - They are pregnant or breast feeding.
- - They have a history of a venous or arterial thrombosis that was not associated to a central line.
- - They have active infections such as hepatitis or fungal infections.
- - They have active diarhhea.
- - They have had an allogeneic stem cell transplant (received stem cell from someone else) - They can't cooperate with the special precautions that are needed for this trial.
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 0: Exploratory study involving very limited human exposure to the drug to determine whether a drug is modulating its target.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
|New Approaches to Neuroblastoma Therapy Consortium|
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
|Countries||Canada, United States|
The disease, disorder, syndrome, illness, or injury that is being studied.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Cook Children's Healthcare System
Fort Worth, Texas, 76104
Meaghan Granger, MD
Children's Hospital Boston
Boston, Massachusetts, 02115
Suzanne Shusterman, MD
Lucile Salter Packer Children's Hospital
Palo Alto, California, 94304
Sheri Spunt, MD
Hospital for Sick Children
Toronto, Ontario, M5G1X8
Meredith Irwin, MD